BVCF Overview
- Investor Type
- Venture Capital
- Status
- Active
- Professionals
- 15

- Investments
- 59
- Portfolio
- 25
- Exits
- 28

BVCF General Information
Description
BVCF is a venture capital firm founded in 2005 that focuses on life sciences and healthcare sectors in China. The firm invests across China and the United States including healthcare services, innovative biologic, in-vitro diagnostics (molecular diagnostics), high value medical equipment and consumables and medical big data and mobile medicine.
Contact Information
- 763 Mengzi Road
- Suite 2606
- Shanghai, 200023
- China
BVCF Investments (59)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
---|---|---|---|---|---|---|
Oculis | 01-Dec-2021 | Later Stage VC | 00.000 | Drug Discovery | Clinical Trials - Phase 2 | |
000000000 | 04-Nov-2021 | 00000 00000 | 0000 | Drug Discovery | Clinical Trials - Phase 1 | 000 0000 00.0 |
000000 | 28-Apr-2021 | 00000 00000 | 000.00 | Drug Discovery | Clinical Trials - Phase 2 | 000 0000 00.0 |
000000 | 24-Feb-2021 | 00000 00000 | Clinics/Outpatient Services | Generating Revenue | ||
0000 0000 | 09-Feb-2021 | 00000 00000 | 0000 | Biotechnology | Clinical Trials - Phase 1 | |
0000 0000000 | 26-Jan-2021 | 00 000000000 | 0000 | Drug Discovery | Profitable | |
0000 000000000 | 07-Jan-2021 | 00000 00000 | Drug Discovery | Clinical Trials - General | ||
000000000 00000000 | 04-Jan-2021 | 00000 00000 | 000.00 | Drug Discovery | Clinical Trials - General | |
MicuRx Pharmaceuticals | 20-Oct-2020 | Secondary Transaction - Private | 000.00 | Pharmaceuticals | Generating Revenue | 00000 0000 |
Seinda | 23-Sep-2020 | Later Stage VC | Diagnostic Equipment | Generating Revenue |
BVCF Exits (28)
Company Name | Exit Date | Exit Type | Exit Size |
---|---|---|---|
Clarus Therapeutics | 09-Sep-2021 | Reverse Merger | 000.00 |
0000000 0000000000 | 17-Jun-2021 | 000 | 00000 |
0000000 | 21-May-2021 | 000 | 000.00 |
000000 | 29-Jan-2021 | 00 000000000000000 | 000.00 |
000000000 | 15-Jan-2021 | 000 | 00000 |
0000000000 | 20-Oct-2020 | 000000000 00000000 | 000.00 |
000000 000000000 | 24-Sep-2020 | 000000000000000000 | |
000000 0000000000 | 12-Aug-2020 | 000 | 00000 |
BioNTech | 10-Oct-2019 | IPO | 00000 |
Stealth BioTherapeutics | 15-Feb-2019 | IPO | 0000 |
BVCF Fund Performance
Fund Name | Vintage | Size | Dry Powder | DPI | RVPI | TVPI | IRR |
---|
This information is available in the PitchBook Platform. To explore BVCF‘s full profile, request access.
Request a free trialBVCF Investments by Industry, Year, and Region
Investments by Industry

Investments by Year

Investments by Region

PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.
Request a free trialBVCF Team (16)
Name | Title | Deals | Funds | Boards | Office |
---|---|---|---|---|---|
Mengqi Chen | Chief Financial Officer | Shanghai, China | |||
Davis Yang | Managing Director | 0 | 0 | 0 | Shanghai, China |
Bing Zhuo | Partner & Head of Beijing Office | 0 | 0 | 0 | Shanghai, China |
Hong Lin | Partner | Shanghai, China | |||
Yi Li Ph.D | Partner | Shanghai, China |
BVCF Co-Investors (34)
Name | With | Exits | Lead Partner | Series | Industry |
---|---|---|---|---|---|
Pivotal Life Sciences | 2 | 0 |
![]() |
![]() |
|
Bay City Capital | 0 | 0 |
![]() |
![]() |
|
DT Capital Partners | 0 |
![]() |
![]() |
||
Earlybird Venture Capital | 0 | 0 |
![]() |
![]() |
|
The Invus Group | 0 |
![]() |
![]() |